Prognostic Assessment and Adjuvant Treatment Strategies Within Early-Stage, Sporadic Triple Negative Breast Cancer Patients

Abstract

An adjuvant chemotherapeutic standard has not been identified in triple negative breast cancer (TNBC) yet. One hundred and forty-one adjuvant treated TNBC patients had a median follow-up of 71 months. Larger tumor size (p = .005) and positive lymph-node status (p = .033) were associated with a significant shorter overall survival. Sixty-one percent of patients received anthracycline-containing chemotherapy, 28.4% a non-anthracycline-containing regimen, and 10.6% an anthracycline/taxane-containing regimen. Overall survival, disease-free survival, local recurrence-free survival and distant disease-free survival did not differ between the chemotherapeutic groups. Non-anthracycline-containing regimen appeared to be an effective treatment in TNBC.

Keywords: :

• Triple negative breast cancer
• Chemotherapy
• Anthracyclines
• CMF
• Overall survival
• Disease-free survival

ACKNOWLEDGMENTS

This work was supported by a research grant from the Austrian Research Promotion Agency (FFG)—Structural Program and by a grant from the City of Vienna, Bürgermeisterfonds, Project number 08073.